Drug Trial Radar · NCT00280956
Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease
Last checked: Nov 20, 2026Latest source record: Jun 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,000
Planned (sponsor's estimate)
Start
Jul 2002
Primary completion
Sep 2004
Study completion Sep 2004
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- Collaborators
- Elan Pharmaceuticals
- First posted
- Jan 24, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the long-term tolerability and safety of natalizumab when administered a dose of 300 mg intravenously (IV) to subjects with Crohn's Disease who have previously participated in studies CD251, CD301, CD303, CD306, or CD307.
Conditions
- Crohn's Disease
Interventions
natalizumabDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety of natalizumab by the number and proportion of subjects with adverse events, and by assessing clinical laboratory parameters and vital signs.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Performed only at CD251, CD301, CD303, CD306, and CD307 sites globally. No general public enrollment. The study is managed from the office of Elan Pharmaceuticals, Inc. in
San Diego, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.